BDBM50029687 CHEMBL3353412::US10227342, Example 57

SMILES CNCCN(C)c1cc(OC)c(Nc2nccc(n2)-c2cn(C)c3ccccc23)cc1NC(=O)C=C

InChI Key InChIKey=ZROCWKZRGJYPTG-UHFFFAOYSA-N

Data  13 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 13 hits for monomerid = 50029687   

LigandPNGBDBM50029687(CHEMBL3353412 | US10227342, Example 57)
Affinity DataIC50: 3.30E+4nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2016
Entry Details Article
PubMed
TargetInsulin-like growth factor 1 receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50029687(CHEMBL3353412 | US10227342, Example 57)
Affinity DataIC50: 1.60E+3nMAssay Description:Inhibition of IGF1R (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2016
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50029687(CHEMBL3353412 | US10227342, Example 57)
Affinity DataIC50: 4.50E+4nMAssay Description:Inhibition of EGFR L858R/T970M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2016
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50029687(CHEMBL3353412 | US10227342, Example 57)
Affinity DataIC50: 2.60E+4nMAssay Description:Inhibition of EGFR exon 19 deletion activating mutant phosphorylation in human PC9 cells after 2 hrs by fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2016
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50029687(CHEMBL3353412 | US10227342, Example 57)
Affinity DataIC50: 7.86E+5nMAssay Description:Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2016
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50029687(CHEMBL3353412 | US10227342, Example 57)
Affinity DataIC50: 26nMAssay Description:Inhibition of EGFR Del ex19 mutant phosphorylation in human PC9 cells preincubated for 2 hrs by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2017
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50029687(CHEMBL3353412 | US10227342, Example 57)
Affinity DataIC50: 45nMAssay Description:Inhibition of EGFR T790M/L858R double mutant phosphorylation in human H1975 cells preincubated for 2 hrs by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2017
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50029687(CHEMBL3353412 | US10227342, Example 57)
Affinity DataIC50: 786nMAssay Description:Inhibition of wild type EGFR phosphorylation in human LoVo cells preincubated for 2 hrs followed by EGF stimulation measured after 30 mins by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2017
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50029687(CHEMBL3353412 | US10227342, Example 57)
Affinity DataIC50: 300nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50029687(CHEMBL3353412 | US10227342, Example 57)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM50029687(CHEMBL3353412 | US10227342, Example 57)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Ariad Pharmaceuticals

US Patent
LigandPNGBDBM50029687(CHEMBL3353412 | US10227342, Example 57)
Affinity DataIC50: 100nMAssay Description:A compound's ability in selectively inhibiting EGFR L858R and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine pro-B cell l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50029687(CHEMBL3353412 | US10227342, Example 57)
Affinity DataIC50: 300nMAssay Description:A compound's ability in selectively inhibiting Her2 exon 20 YVMA insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent